Sudden unexpected death is a terrifying consequence faced by people living with uncontrolled tonic-clonic seizures (TCSs), so ...
GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, can achieve a functional cure in 19% of patients, ...
John Tsai is currently CEO of UK biotech Forcefield Therapeutics and a partner at investment group Syncona. Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, ...
Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...
The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...
As clinical research sites come under growing operational pressure, sponsors and CROs are being challenged to rethink how studies are designed and supported. Protocols are becoming more complex.
If a patient reaches a healthy weight and improves their metabolic profile, the idea of remaining on therapy indefinitely ...
The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...
After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...
Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...
Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results